ABSTRACT: Following concurrent radio-chemotherapy or first-line chemotherapy for advanced non-small cell lung cancer (NSCLC), continuous
maintenance therapy given to patients with stable disease (SD) and follow-up treatment is called consolidation therapy. Concerning
NSCLC patients with a non-operable dry Stage-IIIB (N3) disease, i.e. contra-lateral mediastinal and hilar lymph node, or homolateral/contra-lateral
scalene and Troisier sign, a 2 or 3-course of standard-dosage Taxotere consolidation therapy can be performed a er concurrent
radio-chemotherapy. In pursuance of evidence-based medicine (EBM), low-dose Taxotere maintenance therapy, and biological targeted
therapy of patients with appropriate symptoms are suitable for second-line therapy for moist of the Stage-IIIB (malignant
pleural effusion) and IV patients.
Chinese Journal of Clinical Oncology 04/2012; 5(2):146-149.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 07/2011; 14(7):631-2.
ABSTRACT: Lung cancer is the leading cause for cancer-related mortality and morbidity, and the survival of late-stage non-small cell lung cancer (NSCLC) remains poor. We hereby evaluate conventional chemotherapy followed by immunotherapy using dendritic cells and cytokine-induced killer cells in the treatment for late stage of NSCLC.
Twenty-eight untreated patients suffered from IIIB to IV NSCLC were enrolled in the study between August 2004 and October 2005, and all received four courses of vinorelbine-platinum (NP) chemotherapy. Fourteen of them received conventional NP chemotherapy followed by vaccinated with CEA (605-613) peptide-pulsed autologous dendritic cells and CIK cells. Vaccination was repeated at 30-day intervals for 4 cycles. The adverse effects, time to progression (TTP), and overall survival (OS) in each group were evaluated.
The adverse effect as a result of chemoimmunotherapy was mild and tolerable. Rash, acne, and pruritus were more frequent in the chemoimmunotherapy group than in the chemotherapy group (64.2% vs. 7.1%, P = 0.004). Non-infectious fever was more frequent in the chemoimmunotherapy group than in the chemotherapy group (71.4% vs. 21.4% P = 0.02). Less grade 3/4 fatigue was observed in patients receiving chemoimmunotherapy: 7.1% versus 57.1% in chemotherapy group, P = 0.01. Compared with patients in chemotherapy group, time to progression in chemoimmunotherapy significantly prolonged, with the median improved from 5.2 months (95% CI: 3.3-6.0) to 6.9 months (95% CI: 5.0-8.8) (P = 0.03). The 1-, 2-, and 5-year survival rates were 64.3, 49, and 21.0%, respectively in chemoimmunotherapy group. Overall survival rate showed no statistically difference between two groups (P = 0.18).
Chemoimmunotherapy could alleviate adverse effects of conventional chemotherapy and prolong survival for patients with late-stage NSCLC.
Cancer Immunology and Immunotherapy 06/2011; 60(10):1497-502. · 3.70 Impact Factor
ABSTRACT: Lung lymphoepithelioma-like carcinoma is a rare subtype of large cell carcinomas of the lung. The aim of this study is to retrospectively analyze the clinical characteristics, surgical methods, laboratory inspection, chemotherapy, radiotherapy and prognosis of LELC.
From 2004 to 2008, clinical data were collected from 21 patients who were treated in Shanghai Chest Hospital. The correlation between clinicopathological characteristics and prognosis was evaluated.
Of the 21 patients, 15 patients had lobectomy; 4 patients had wedge resection; 1 patient had pneumonectomy and 1 patient had sleeve resection. 12 patients received chemotherapy and 3 patients received radiotherapy after operation. Until 2009-4-31, 4 patients died, and the median survival time (MST) was 49 months.
Lymphoepitheliomalike carcinoma of the lung is a very rare and unique subtype of large cell carcinomas of the lung, which has a better prognosis with surgical, chemotherapy and radiotherapy.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 11/2009; 12(11):1169-73.
ABSTRACT: Second-line chemotherapy with taxanes for the patients with non-small cell lung cancer (NSCLC), who had disease recurrence or failure in previously treated with platinum-based chemotherapy, has been shown to be effective. Besides docetaxel, paclitaxel, the other available taxane, has also demonstrated potential activity in the same indication in a few studies. The aim of this study is to compare the treatment efficacy and safety between paclitaxel and paclitaxel plus oxaliplatin as the second-line treatment of advanced NSCLC.
Sixty-six patients from Sep 2000 to Sep 2007 whose disease progressed after first-line chemotherapy were enrolled and randomized into 2 groups: one group was administered with only paclitaxel (44 patients), the other was given paclitaxel plus oxaliplatin (22 patients), ECOG 0-2. The regiments were: single agent paclitaxel (175 mg/m(2), d1) or paclitaxel (175 mg/m(2), d1) plus oxaliplatin(130 mg/m(2), d1), 3-4 weeks/cycle.
The overall response rate of single paclitaxel and paclitaxel plus oxaliplatin were 13.6% and 18.2%, respectively. The median time to progression were 3.2 months vs 4.5 months. Median survival time were 6.9 months vs 8.2 months. There were no statistical differences. The haematological toxicities of paclitaxel plus oxaliplatin group were more severe than single agent group: grade 3/4 leukopenia (P=0.039). The rate of nausea, vomiting and acroaesthesia in paclitaxel plus oxaliplatin group was higher than that of single-paclitaxel group, but there were no statistical differences. Other adverse effects were mild.
Singlepaclitaxel administration as the second-lined treatment of advanced NSCLC is tolerable and has the response effect no worse than the combined chemotherapy.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 11/2009; 12(11):1178-83.
ABSTRACT: Non-small cell lung cancer (NSCLC) are more common in elderly people. The elderly patients are usually intolerable to platinum-based chemotherapy for other accompanying diseases. But many recent researches show the age factor is not the absolute contraindication. The aim of this study is to compare the toxic effects, disease progression time and overall survival time between advanced NSCLC patients 60 or older than 60 and younger than 60 who are administrated with palitaxel plus platinum-based agents.
One hundred and ninety two patients were retrospectively divided into two groups according to the age of 60. The regimen is palitaxel (175 mg per square meter on day 1) combined with cisplatin (75 mg per square meter on day1)/carboplatin (ar an area under the curve of 5 mg per millimeter per minute on day 1), 3-4 weeks per cycle.
The respond rate in groups >=60 and <60 were 22.34% vs 24.49%, median time to progression were 4.1 months vs 4.4 months; median overall survival time were 11.8 months vs 12.4 months; one, two and three-year survival rate were 52.1% vs 54.1%, 19.1% vs 20.4%, 9.6% vs 11.2%, respectively, there are no statistical difference. The most common grade 3 or 4 adverse events between groups >=60 and <60 were neutropenia (21.27% and 16.32%, respectively), thrombocytopenia (4.26% and 2.04%), there were no statistical difference. Nonhaematologial toxicities are mild.
Palitaxel plus platinum-based chemotherapy in elderly patients is effective and tolerable.
Zhongguo fei ai za zhi = Chinese journal of lung cancer 04/2009; 12(4):327-31.